Funding Models in Biotech

MBBP Life Sciences Series - Panel 3

THIS EVENT IS NOW FULL.
Please contact Dori Corley at dcorley@mbbp.com to be added to the waitlist. 

Today’s financing environment for emerging biotech companies presents a number of challenges. Venture capital funds are ever more cautious about taking risk, and some players have departed the field at the early stage. Government grants have also closed their spigots in recent years, as the volume of government funding has plummeted dramatically. However, new players have entered the fray in the last few years, including family offices, super angels, strategic partners and foreign investors, replacing the investment dollars previously offered by institutional investors.  So where does an emerging biotech company forage for precious dollars? Come join us on September 22nd at the CIC in Cambridge to hear a panel of experts discuss these trends. At the event, you will discover, among other ideas:

• Where and how to find the new players;
• What areas of interest are these players financing;
• How to optimize your chances of success;
• What are deal structures looking like?

Moderator:
John Hession, Partner, Morse, Barnes-Brown & Pendleton, PC - @morsebarnes

Panel:
Josh Hamermesh, Vice President, Locust Walk

Dana Callow, Managing General Partner, Boston Millennia Partners

John Gustofson, Sr. Director, AbbVie Ventures